CA2702760C - Variants mutants du facteur de croissance i semblable a l'insuline (igf) - Google Patents

Variants mutants du facteur de croissance i semblable a l'insuline (igf) Download PDF

Info

Publication number: CA2702760C
Authority: CA; Canada
Prior art keywords: igf; igfbp; insulin; replaced; binding
Prior art date: 1999-01-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA2702760A

Other languages

English (en)

Other versions

CA2702760A1 (fr

Inventor

Yves Dubaquie

Henry Lowman

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Genentech Inc

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-01-06

Filing date

2000-01-05

Publication date

2015-02-24

2000-01-05 Application filed by Genentech Inc filed Critical Genentech Inc

2000-01-05 Priority claimed from CA2356257A external-priority patent/CA2356257C/fr

2000-07-13 Publication of CA2702760A1 publication Critical patent/CA2702760A1/fr

2015-02-24 Application granted granted Critical

2015-02-24 Publication of CA2702760C publication Critical patent/CA2702760C/fr

2020-01-05 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

108090000723 Insulin-Like Growth Factor I Proteins 0.000 title claims abstract description 301
102000013275 Somatomedins Human genes 0.000 title description 98
102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims abstract description 203
235000001014 amino acid Nutrition 0.000 claims description 175
150000001413 amino acids Chemical group 0.000 claims description 120
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 87
235000004279 alanine Nutrition 0.000 claims description 77
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 60
239000004471 Glycine Substances 0.000 claims description 45
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 43
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 31
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 31
239000000203 mixture Substances 0.000 claims description 24
238000006467 substitution reaction Methods 0.000 claims description 23
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 22
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 14
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 13
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 7
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 277
102000004877 Insulin Human genes 0.000 abstract description 149
108090001061 Insulin Proteins 0.000 abstract description 148
229940125396 insulin Drugs 0.000 abstract description 139
102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 abstract description 94
108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 abstract description 94
102000004375 Insulin-like growth factor-binding protein 1 Human genes 0.000 abstract description 71
108090000957 Insulin-like growth factor-binding protein 1 Proteins 0.000 abstract description 71
239000000556 agonist Substances 0.000 abstract description 6
108090000765 processed proteins & peptides Proteins 0.000 description 179
229940024606 amino acid Drugs 0.000 description 165
230000027455 binding Effects 0.000 description 103
102000028416 insulin-like growth factor binding Human genes 0.000 description 78
108091022911 insulin-like growth factor binding Proteins 0.000 description 78
238000000034 method Methods 0.000 description 75
108090000623 proteins and genes Proteins 0.000 description 67
102000004196 processed proteins & peptides Human genes 0.000 description 63
125000003275 alpha amino acid group Chemical group 0.000 description 60
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 55
COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 55
241000282414 Homo sapiens Species 0.000 description 53
102000004169 proteins and genes Human genes 0.000 description 46
235000018102 proteins Nutrition 0.000 description 45
238000011282 treatment Methods 0.000 description 41
210000004027 cell Anatomy 0.000 description 39
-1 Mac 25 (IGFBP-7) Proteins 0.000 description 37
108010076181 Proinsulin Proteins 0.000 description 36
241000124008 Mammalia Species 0.000 description 34
235000002374 tyrosine Nutrition 0.000 description 31
125000006239 protecting group Chemical group 0.000 description 30
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 28
102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 26
229920005989 resin Polymers 0.000 description 26
239000011347 resin Substances 0.000 description 26
108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 25
208000035475 disorder Diseases 0.000 description 25
230000000694 effects Effects 0.000 description 23
239000013598 vector Substances 0.000 description 22
101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 20
102000044162 human IGF1 Human genes 0.000 description 20
238000002965 ELISA Methods 0.000 description 19
238000002474 experimental method Methods 0.000 description 19
102000005962 receptors Human genes 0.000 description 19
108020003175 receptors Proteins 0.000 description 19
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 18
102000014914 Carrier Proteins Human genes 0.000 description 17
108091008324 binding proteins Proteins 0.000 description 17
210000004369 blood Anatomy 0.000 description 17
239000008280 blood Substances 0.000 description 17
206010012601 diabetes mellitus Diseases 0.000 description 17
102000037865 fusion proteins Human genes 0.000 description 17
108020001507 fusion proteins Proteins 0.000 description 17
238000005859 coupling reaction Methods 0.000 description 16
229960002989 glutamic acid Drugs 0.000 description 16
229920001184 polypeptide Polymers 0.000 description 16
235000013922 glutamic acid Nutrition 0.000 description 15
239000004220 glutamic acid Substances 0.000 description 15
241000588724 Escherichia coli Species 0.000 description 13
239000003795 chemical substances by application Substances 0.000 description 13
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 13
230000003993 interaction Effects 0.000 description 13
239000002245 particle Substances 0.000 description 13
239000000243 solution Substances 0.000 description 13
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 12
210000001519 tissue Anatomy 0.000 description 12
102220480405 H/ACA ribonucleoprotein complex subunit DKC1_F49A_mutation Human genes 0.000 description 11
238000010168 coupling process Methods 0.000 description 11
238000001727 in vivo Methods 0.000 description 11
102000039446 nucleic acids Human genes 0.000 description 11
108020004707 nucleic acids Proteins 0.000 description 11
150000007523 nucleic acids Chemical class 0.000 description 11
230000009471 action Effects 0.000 description 10
230000015572 biosynthetic process Effects 0.000 description 10
238000006243 chemical reaction Methods 0.000 description 10
230000008878 coupling Effects 0.000 description 10
239000012530 fluid Substances 0.000 description 10
230000035772 mutation Effects 0.000 description 10
238000000746 purification Methods 0.000 description 10
238000003786 synthesis reaction Methods 0.000 description 10
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 9
239000004473 Threonine Substances 0.000 description 9
239000003472 antidiabetic agent Substances 0.000 description 9
210000004899 c-terminal region Anatomy 0.000 description 9
LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 description 9
239000003153 chemical reaction reagent Substances 0.000 description 9
229940126904 hypoglycaemic agent Drugs 0.000 description 9
239000004026 insulin derivative Substances 0.000 description 9
238000002823 phage display Methods 0.000 description 9
230000002829 reductive effect Effects 0.000 description 9
108010001127 Insulin Receptor Proteins 0.000 description 8
102000003746 Insulin Receptor Human genes 0.000 description 8
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
238000012867 alanine scanning Methods 0.000 description 8
235000018417 cysteine Nutrition 0.000 description 8
230000007423 decrease Effects 0.000 description 8
238000009472 formulation Methods 0.000 description 8
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Chemical group OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 8
125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 8
239000013612 plasmid Substances 0.000 description 8
239000000047 product Substances 0.000 description 8
210000002966 serum Anatomy 0.000 description 8
108010033419 somatotropin-binding protein Proteins 0.000 description 8
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 8
208000001072 type 2 diabetes mellitus Diseases 0.000 description 8
IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 7
108020004414 DNA Proteins 0.000 description 7
102400001066 Growth hormone-binding protein Human genes 0.000 description 7
241000282412 Homo Species 0.000 description 7
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 7
208000008589 Obesity Diseases 0.000 description 7
239000002253 acid Substances 0.000 description 7
238000004458 analytical method Methods 0.000 description 7
239000000872 buffer Substances 0.000 description 7
239000012634 fragment Substances 0.000 description 7
230000006870 function Effects 0.000 description 7
230000014509 gene expression Effects 0.000 description 7
230000003345 hyperglycaemic effect Effects 0.000 description 7
238000002347 injection Methods 0.000 description 7
239000007924 injection Substances 0.000 description 7
238000002703 mutagenesis Methods 0.000 description 7
231100000350 mutagenesis Toxicity 0.000 description 7
235000020824 obesity Nutrition 0.000 description 7
230000004224 protection Effects 0.000 description 7
230000009467 reduction Effects 0.000 description 7
230000000638 stimulation Effects 0.000 description 7
239000000126 substance Substances 0.000 description 7
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 6
102000005237 Isophane Insulin Human genes 0.000 description 6
108010081368 Isophane Insulin Proteins 0.000 description 6
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
230000004071 biological effect Effects 0.000 description 6
239000003431 cross linking reagent Substances 0.000 description 6
125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 6
108700001680 des-(1-3)- insulin-like growth factor 1 Proteins 0.000 description 6
238000010494 dissociation reaction Methods 0.000 description 6
230000005593 dissociations Effects 0.000 description 6
229910000040 hydrogen fluoride Inorganic materials 0.000 description 6
230000000580 secretagogue effect Effects 0.000 description 6
239000007790 solid phase Substances 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 5
102220497135 5-hydroxytryptamine receptor 3B_F25A_mutation Human genes 0.000 description 5
241000894006 Bacteria Species 0.000 description 5
102000018997 Growth Hormone Human genes 0.000 description 5
108010051696 Growth Hormone Proteins 0.000 description 5
102100039256 Growth hormone secretagogue receptor type 1 Human genes 0.000 description 5
101710202385 Growth hormone secretagogue receptor type 1 Proteins 0.000 description 5
206010053759 Growth retardation Diseases 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
238000005481 NMR spectroscopy Methods 0.000 description 5
108020004511 Recombinant DNA Proteins 0.000 description 5
102220496652 Signal peptide, CUB and EGF-like domain-containing protein 1_R36A_mutation Human genes 0.000 description 5
125000003277 amino group Chemical group 0.000 description 5
238000003776 cleavage reaction Methods 0.000 description 5
238000004132 cross linking Methods 0.000 description 5
239000013078 crystal Substances 0.000 description 5
239000003814 drug Substances 0.000 description 5
238000005516 engineering process Methods 0.000 description 5
150000002148 esters Chemical class 0.000 description 5
230000004927 fusion Effects 0.000 description 5
238000001415 gene therapy Methods 0.000 description 5
230000012010 growth Effects 0.000 description 5
239000000122 growth hormone Substances 0.000 description 5
231100000001 growth retardation Toxicity 0.000 description 5
238000001802 infusion Methods 0.000 description 5
201000006370 kidney failure Diseases 0.000 description 5
125000005647 linker group Chemical group 0.000 description 5
239000007788 liquid Substances 0.000 description 5
239000000463 material Substances 0.000 description 5
229920000136 polysorbate Polymers 0.000 description 5
230000010076 replication Effects 0.000 description 5
150000003839 salts Chemical class 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
241000283690 Bos taurus Species 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
108010031794 IGF Type 1 Receptor Proteins 0.000 description 4
206010022489 Insulin Resistance Diseases 0.000 description 4
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
108091005804 Peptidases Proteins 0.000 description 4
239000004365 Protease Substances 0.000 description 4
208000001647 Renal Insufficiency Diseases 0.000 description 4
208000020221 Short stature Diseases 0.000 description 4
229940123464 Thiazolidinedione Drugs 0.000 description 4
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
230000000747 cardiac effect Effects 0.000 description 4
210000003169 central nervous system Anatomy 0.000 description 4
230000008859 change Effects 0.000 description 4
125000004122 cyclic group Chemical group 0.000 description 4
230000003247 decreasing effect Effects 0.000 description 4
238000012217 deletion Methods 0.000 description 4
230000037430 deletion Effects 0.000 description 4
150000002019 disulfides Chemical class 0.000 description 4
229940079593 drug Drugs 0.000 description 4
125000000524 functional group Chemical group 0.000 description 4
239000003102 growth factor Substances 0.000 description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
239000003446 ligand Substances 0.000 description 4
230000000670 limiting effect Effects 0.000 description 4
150000002632 lipids Chemical class 0.000 description 4
239000002502 liposome Substances 0.000 description 4
238000005259 measurement Methods 0.000 description 4
239000012528 membrane Substances 0.000 description 4
239000000178 monomer Substances 0.000 description 4
238000010647 peptide synthesis reaction Methods 0.000 description 4
239000008194 pharmaceutical composition Substances 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
230000008569 process Effects 0.000 description 4
230000008929 regeneration Effects 0.000 description 4
238000011069 regeneration method Methods 0.000 description 4
238000012552 review Methods 0.000 description 4
102200150062 rs121909262 Human genes 0.000 description 4
230000007017 scission Effects 0.000 description 4
241000894007 species Species 0.000 description 4
239000007858 starting material Substances 0.000 description 4
238000013268 sustained release Methods 0.000 description 4
239000012730 sustained-release form Substances 0.000 description 4
239000003826 tablet Substances 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
239000003981 vehicle Substances 0.000 description 4
ILOHMCCDCAUTQF-JESKXYQHSA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-aminopropanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide;dihydrochloride Chemical compound Cl.Cl.C([C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](C)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(=O)[C@H](N)C)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 ILOHMCCDCAUTQF-JESKXYQHSA-N 0.000 description 3
102220554190 APC membrane recruitment protein 1_D45A_mutation Human genes 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
206010007733 Catabolic state Diseases 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
101000840577 Homo sapiens Insulin-like growth factor-binding protein 7 Proteins 0.000 description 3
102000004372 Insulin-like growth factor binding protein 2 Human genes 0.000 description 3
108090000964 Insulin-like growth factor binding protein 2 Proteins 0.000 description 3
102100029228 Insulin-like growth factor-binding protein 7 Human genes 0.000 description 3
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 3
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
108010052285 Membrane Proteins Proteins 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
108091028043 Nucleic acid sequence Proteins 0.000 description 3
108010076504 Protein Sorting Signals Proteins 0.000 description 3
102100022831 Somatoliberin Human genes 0.000 description 3
229940100389 Sulfonylurea Drugs 0.000 description 3
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical group [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
230000001133 acceleration Effects 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
125000005076 adamantyloxycarbonyl group Chemical group C12(CC3CC(CC(C1)C3)C2)OC(=O)* 0.000 description 3
125000000539 amino acid group Chemical group 0.000 description 3
238000013459 approach Methods 0.000 description 3
238000003556 assay Methods 0.000 description 3
230000008901 benefit Effects 0.000 description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
239000013060 biological fluid Substances 0.000 description 3
230000037396 body weight Effects 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
125000004432 carbon atom Chemical group C* 0.000 description 3
239000000969 carrier Substances 0.000 description 3
208000020832 chronic kidney disease Diseases 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
230000006378 damage Effects 0.000 description 3
238000001514 detection method Methods 0.000 description 3
201000010099 disease Diseases 0.000 description 3
238000009826 distribution Methods 0.000 description 3
125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 3
229960004580 glibenclamide Drugs 0.000 description 3
239000008103 glucose Substances 0.000 description 3
ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 3
229940088597 hormone Drugs 0.000 description 3
239000005556 hormone Substances 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
239000003547 immunosorbent Substances 0.000 description 3
230000006872 improvement Effects 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 3
208000017169 kidney disease Diseases 0.000 description 3
239000012139 lysis buffer Substances 0.000 description 3
239000002609 medium Substances 0.000 description 3
229930182817 methionine Natural products 0.000 description 3
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 3
230000007935 neutral effect Effects 0.000 description 3
230000003169 placental effect Effects 0.000 description 3
229960000208 pralmorelin Drugs 0.000 description 3
229940048914 protamine Drugs 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
238000007363 ring formation reaction Methods 0.000 description 3
238000010532 solid phase synthesis reaction Methods 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
239000000725 suspension Substances 0.000 description 3
102220535569 tRNA wybutosine-synthesizing protein 5_P63A_mutation Human genes 0.000 description 3
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
238000012546 transfer Methods 0.000 description 3
GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 3
229960001641 troglitazone Drugs 0.000 description 3
GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 3
230000029663 wound healing Effects 0.000 description 3
WZHKXNSOCOQYQX-FUAFALNISA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 WZHKXNSOCOQYQX-FUAFALNISA-N 0.000 description 2
BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
102220554063 APC membrane recruitment protein 1_T41A_mutation Human genes 0.000 description 2
208000009304 Acute Kidney Injury Diseases 0.000 description 2
102220468483 Annexin A2_Y24A_mutation Human genes 0.000 description 2
HAVKMRGWNXMCDR-STQMWFEESA-N Arg-Gly-Phe Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O HAVKMRGWNXMCDR-STQMWFEESA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
102220530016 Bifunctional apoptosis regulator_F23A_mutation Human genes 0.000 description 2
229940123208 Biguanide Drugs 0.000 description 2
125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
206010006895 Cachexia Diseases 0.000 description 2
101800005309 Carboxy-terminal peptide Proteins 0.000 description 2
208000017667 Chronic Disease Diseases 0.000 description 2
208000014311 Cushing syndrome Diseases 0.000 description 2
GCDLPNRHPWBKJJ-WDSKDSINSA-N Cys-Gly-Glu Chemical compound [H]N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O GCDLPNRHPWBKJJ-WDSKDSINSA-N 0.000 description 2
XTHUKRLJRUVVBF-WHFBIAKZSA-N Cys-Gly-Ser Chemical compound SC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O XTHUKRLJRUVVBF-WHFBIAKZSA-N 0.000 description 2
238000001712 DNA sequencing Methods 0.000 description 2
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
102220562239 Disintegrin and metalloproteinase domain-containing protein 11_F16P_mutation Human genes 0.000 description 2
201000005948 Donohue syndrome Diseases 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
241000283073 Equus caballus Species 0.000 description 2
241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 2
241001524679 Escherichia virus M13 Species 0.000 description 2
IWUFOVSLWADEJC-AVGNSLFASA-N Gln-His-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O IWUFOVSLWADEJC-AVGNSLFASA-N 0.000 description 2
ITYRYNUZHPNCIK-GUBZILKMSA-N Glu-Ala-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O ITYRYNUZHPNCIK-GUBZILKMSA-N 0.000 description 2
ZJICFHQSPWFBKP-AVGNSLFASA-N Glu-Asn-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZJICFHQSPWFBKP-AVGNSLFASA-N 0.000 description 2
JJGBXTYGTKWGAT-YUMQZZPRSA-N Gly-Pro-Glu Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O JJGBXTYGTKWGAT-YUMQZZPRSA-N 0.000 description 2
102220534768 Glycogen phosphorylase, liver form_D12A_mutation Human genes 0.000 description 2
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
TWROVBNEHJSXDG-IHRRRGAJSA-N His-Leu-Val Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O TWROVBNEHJSXDG-IHRRRGAJSA-N 0.000 description 2
101000976075 Homo sapiens Insulin Proteins 0.000 description 2
101000825742 Homo sapiens Somatoliberin Proteins 0.000 description 2
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
206010060378 Hyperinsulinaemia Diseases 0.000 description 2
102000038455 IGF Type 1 Receptor Human genes 0.000 description 2
102000004371 Insulin-like growth factor binding protein 5 Human genes 0.000 description 2
108090000961 Insulin-like growth factor binding protein 5 Proteins 0.000 description 2
102000004883 Insulin-like growth factor-binding protein 6 Human genes 0.000 description 2
108090001014 Insulin-like growth factor-binding protein 6 Proteins 0.000 description 2
102220475986 Keratin, type I cytoskeletal 10_Y26F_mutation Human genes 0.000 description 2
LHSGPCFBGJHPCY-UHFFFAOYSA-N L-leucine-L-tyrosine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-UHFFFAOYSA-N 0.000 description 2
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
108010077977 Lente Insulin Proteins 0.000 description 2
102000018697 Membrane Proteins Human genes 0.000 description 2
102000008300 Mutant Proteins Human genes 0.000 description 2
108010021466 Mutant Proteins Proteins 0.000 description 2
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 2
PYUSHNKNPOHWEZ-YFKPBYRVSA-N N-formyl-L-methionine Chemical group CSCC[C@@H](C(O)=O)NC=O PYUSHNKNPOHWEZ-YFKPBYRVSA-N 0.000 description 2
ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 2
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
125000000729 N-terminal amino-acid group Chemical group 0.000 description 2
208000012902 Nervous system disease Diseases 0.000 description 2
208000025966 Neurological disease Diseases 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
208000001132 Osteoporosis Diseases 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
241001494479 Pecora Species 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
108010033276 Peptide Fragments Proteins 0.000 description 2
102000007079 Peptide Fragments Human genes 0.000 description 2
108010067902 Peptide Library Proteins 0.000 description 2
GOUWCZRDTWTODO-YDHLFZDLSA-N Phe-Val-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O GOUWCZRDTWTODO-YDHLFZDLSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
102000007327 Protamines Human genes 0.000 description 2
108010007568 Protamines Proteins 0.000 description 2
102220534424 Pseudouridylate synthase 7 homolog-like protein_S34A_mutation Human genes 0.000 description 2
102220534543 Pseudouridylate synthase 7 homolog-like protein_S35A_mutation Human genes 0.000 description 2
208000033626 Renal failure acute Diseases 0.000 description 2
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
108091006629 SLC13A2 Proteins 0.000 description 2
102220599431 Serum amyloid A-1 protein_V70A_mutation Human genes 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
208000026928 Turner syndrome Diseases 0.000 description 2
TWAVEIJGFCBWCG-JYJNAYRXSA-N Tyr-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)N TWAVEIJGFCBWCG-JYJNAYRXSA-N 0.000 description 2
CDKZJGMPZHPAJC-ULQDDVLXSA-N Tyr-Leu-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 CDKZJGMPZHPAJC-ULQDDVLXSA-N 0.000 description 2
108010061168 Ultralente Insulin Proteins 0.000 description 2
241000251539 Vertebrata <Metazoa> Species 0.000 description 2
241000700605 Viruses Species 0.000 description 2
102220469750 Voltage-dependent L-type calcium channel subunit beta-2_R50A_mutation Human genes 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
230000004913 activation Effects 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
150000001408 amides Chemical group 0.000 description 2
230000001195 anabolic effect Effects 0.000 description 2
238000004873 anchoring Methods 0.000 description 2
RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000001588 bifunctional effect Effects 0.000 description 2
150000004283 biguanides Chemical class 0.000 description 2
239000012148 binding buffer Substances 0.000 description 2
210000001124 body fluid Anatomy 0.000 description 2
239000010839 body fluid Substances 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
229910052796 boron Inorganic materials 0.000 description 2
WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
239000004202 carbamide Substances 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
230000001925 catabolic effect Effects 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
208000022831 chronic renal failure syndrome Diseases 0.000 description 2
238000010367 cloning Methods 0.000 description 2
230000002860 competitive effect Effects 0.000 description 2
230000009918 complex formation Effects 0.000 description 2
239000003636 conditioned culture medium Substances 0.000 description 2
239000007822 coupling agent Substances 0.000 description 2
108010016616 cysteinylglycine Proteins 0.000 description 2
108010073977 decorsin Proteins 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
230000009699 differential effect Effects 0.000 description 2
FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 2
238000006073 displacement reaction Methods 0.000 description 2
239000000284 extract Substances 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 2
229960001381 glipizide Drugs 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
230000002641 glycemic effect Effects 0.000 description 2
150000002333 glycines Chemical class 0.000 description 2
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
208000037824 growth disorder Diseases 0.000 description 2
208000019622 heart disease Diseases 0.000 description 2
230000013632 homeostatic process Effects 0.000 description 2
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
230000003451 hyperinsulinaemic effect Effects 0.000 description 2
201000008980 hyperinsulinism Diseases 0.000 description 2
208000026278 immune system disease Diseases 0.000 description 2
230000006698 induction Effects 0.000 description 2
208000014674 injury Diseases 0.000 description 2
238000007689 inspection Methods 0.000 description 2
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
108010012058 leucyltyrosine Proteins 0.000 description 2
239000012931 lyophilized formulation Substances 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
229960003105 metformin Drugs 0.000 description 2
238000006140 methanolysis reaction Methods 0.000 description 2
230000002297 mitogenic effect Effects 0.000 description 2
201000006417 multiple sclerosis Diseases 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
201000006938 muscular dystrophy Diseases 0.000 description 2
230000001537 neural effect Effects 0.000 description 2
230000000926 neurological effect Effects 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
229960003104 ornithine Drugs 0.000 description 2
125000001151 peptidyl group Chemical group 0.000 description 2
208000033808 peripheral neuropathy Diseases 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 2
229960003243 phenformin Drugs 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
210000002381 plasma Anatomy 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
230000002265 prevention Effects 0.000 description 2
235000013930 proline Nutrition 0.000 description 2
125000001500 prolyl group Chemical class [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
230000006337 proteolytic cleavage Effects 0.000 description 2
239000003488 releasing hormone Substances 0.000 description 2
230000008439 repair process Effects 0.000 description 2
238000004007 reversed phase HPLC Methods 0.000 description 2
230000000630 rising effect Effects 0.000 description 2
102220003317 rs137852699 Human genes 0.000 description 2
102200067146 rs80357017 Human genes 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
230000028327 secretion Effects 0.000 description 2
238000013207 serial dilution Methods 0.000 description 2
108010048818 seryl-histidine Proteins 0.000 description 2
239000007787 solid Substances 0.000 description 2
230000007928 solubilization Effects 0.000 description 2
238000005063 solubilization Methods 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 2
230000008093 supporting effect Effects 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
150000001467 thiazolidinediones Chemical class 0.000 description 2
125000003396 thiol group Chemical group [H]S* 0.000 description 2
230000002992 thymic effect Effects 0.000 description 2
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
239000011701 zinc Substances 0.000 description 2
229910052725 zinc Inorganic materials 0.000 description 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
NWQWNCILOXTTHF-HLCSKTDOSA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](NC(=O)[C@@H](N)C)C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CNC=N1 NWQWNCILOXTTHF-HLCSKTDOSA-N 0.000 description 1
UHPQFNXOFFPHJW-UHFFFAOYSA-N (4-methylphenyl)-phenylmethanamine Chemical compound C1=CC(C)=CC=C1C(N)C1=CC=CC=C1 UHPQFNXOFFPHJW-UHFFFAOYSA-N 0.000 description 1
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 description 1
125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
125000006281 4-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Br)C([H])([H])* 0.000 description 1
125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 1
102220497093 5-hydroxytryptamine receptor 3B_K68A_mutation Human genes 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
102220554131 APC membrane recruitment protein 1_E58A_mutation Human genes 0.000 description 1
102220554200 APC membrane recruitment protein 1_K27A_mutation Human genes 0.000 description 1
102220553788 APC membrane recruitment protein 1_K65A_mutation Human genes 0.000 description 1
SUMYEVXWCAYLLJ-GUBZILKMSA-N Ala-Leu-Gln Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O SUMYEVXWCAYLLJ-GUBZILKMSA-N 0.000 description 1
ADSGHMXEAZJJNF-DCAQKATOSA-N Ala-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N ADSGHMXEAZJJNF-DCAQKATOSA-N 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
108010032595 Antibody Binding Sites Proteins 0.000 description 1
102100033367 Appetite-regulating hormone Human genes 0.000 description 1
DBKNLHKEVPZVQC-LPEHRKFASA-N Arg-Ala-Pro Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(O)=O DBKNLHKEVPZVQC-LPEHRKFASA-N 0.000 description 1
HPKSHFSEXICTLI-CIUDSAMLSA-N Arg-Glu-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O HPKSHFSEXICTLI-CIUDSAMLSA-N 0.000 description 1
RFXXUWGNVRJTNQ-QXEWZRGKSA-N Arg-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)N RFXXUWGNVRJTNQ-QXEWZRGKSA-N 0.000 description 1
OTZMRMHZCMZOJZ-SRVKXCTJSA-N Arg-Leu-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O OTZMRMHZCMZOJZ-SRVKXCTJSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
229910015900 BF3 Inorganic materials 0.000 description 1
244000063299 Bacillus subtilis Species 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
108010075254 C-Peptide Proteins 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
108090000565 Capsid Proteins Proteins 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
102100023321 Ceruloplasmin Human genes 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
206010053547 Congenital generalised lipodystrophy Diseases 0.000 description 1
201000006705 Congenital generalized lipodystrophy Diseases 0.000 description 1
244000265913 Crataegus laevigata Species 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
108010069514 Cyclic Peptides Proteins 0.000 description 1
102000001189 Cyclic Peptides Human genes 0.000 description 1
PJWWRFATQTVXHA-UHFFFAOYSA-N Cyclohexylaminopropanesulfonic acid Chemical compound OS(=O)(=O)CCCNC1CCCCC1 PJWWRFATQTVXHA-UHFFFAOYSA-N 0.000 description 1
XABFFGOGKOORCG-CIUDSAMLSA-N Cys-Asp-Leu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O XABFFGOGKOORCG-CIUDSAMLSA-N 0.000 description 1
KOHBWQDSVCARMI-BWBBJGPYSA-N Cys-Cys-Thr Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KOHBWQDSVCARMI-BWBBJGPYSA-N 0.000 description 1
GGRDJANMZPGMNS-CIUDSAMLSA-N Cys-Ser-Leu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O GGRDJANMZPGMNS-CIUDSAMLSA-N 0.000 description 1
102220501359 Cytosolic iron-sulfur assembly component 3_I43A_mutation Human genes 0.000 description 1
102220501366 Cytosolic iron-sulfur assembly component 3_R55A_mutation Human genes 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
208000016192 Demyelinating disease Diseases 0.000 description 1
206010012305 Demyelination Diseases 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
102220511094 Endothelial cell-specific molecule 1_L14A_mutation Human genes 0.000 description 1
108010092674 Enkephalins Proteins 0.000 description 1
102220519607 Enoyl-CoA hydratase, mitochondrial_Y60A_mutation Human genes 0.000 description 1
241000588921 Enterobacteriaceae Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102220508665 Ephrin type-A receptor 4_Q40A_mutation Human genes 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241001522878 Escherichia coli B Species 0.000 description 1
108010074860 Factor Xa Proteins 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
GNDJOCGXGLNCKY-ACZMJKKPSA-N Gln-Cys-Cys Chemical compound N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(O)=O GNDJOCGXGLNCKY-ACZMJKKPSA-N 0.000 description 1
ININBLZFFVOQIO-JHEQGTHGSA-N Gln-Thr-Gly Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCC(=O)N)N)O ININBLZFFVOQIO-JHEQGTHGSA-N 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
MXPBQDFWIMBACQ-ACZMJKKPSA-N Glu-Cys-Cys Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(O)=O MXPBQDFWIMBACQ-ACZMJKKPSA-N 0.000 description 1
102220563888 Glucagon receptor_P66A_mutation Human genes 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
MFVQGXGQRIXBPK-WDSKDSINSA-N Gly-Ala-Glu Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O MFVQGXGQRIXBPK-WDSKDSINSA-N 0.000 description 1
IWAXHBCACVWNHT-BQBZGAKWSA-N Gly-Asp-Arg Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IWAXHBCACVWNHT-BQBZGAKWSA-N 0.000 description 1
QAMMIGULQSIRCD-IRXDYDNUSA-N Gly-Phe-Tyr Chemical compound C([C@H](NC(=O)C[NH3+])C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C([O-])=O)C1=CC=CC=C1 QAMMIGULQSIRCD-IRXDYDNUSA-N 0.000 description 1
206010018473 Glycosuria Diseases 0.000 description 1
239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
102100020948 Growth hormone receptor Human genes 0.000 description 1
101710119601 Growth hormone-releasing peptides Proteins 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
101150069554 HIS4 gene Proteins 0.000 description 1
102220625993 HMG box transcription factor BBX_D20A_mutation Human genes 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 description 1
101001081567 Homo sapiens Insulin-like growth factor-binding protein 1 Proteins 0.000 description 1
101001044927 Homo sapiens Insulin-like growth factor-binding protein 3 Proteins 0.000 description 1
101000926206 Homo sapiens Putative glutathione hydrolase 3 proenzyme Proteins 0.000 description 1
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
208000037171 Hypercorticoidism Diseases 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
BCISUQVFDGYZBO-QSFUFRPTSA-N Ile-Val-Asp Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC(O)=O BCISUQVFDGYZBO-QSFUFRPTSA-N 0.000 description 1
YWCJXQKATPNPOE-UKJIMTQDSA-N Ile-Val-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N YWCJXQKATPNPOE-UKJIMTQDSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
108010065920 Insulin Lispro Proteins 0.000 description 1
206010022491 Insulin resistant diabetes Diseases 0.000 description 1
102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 1
102000004369 Insulin-like growth factor-binding protein 4 Human genes 0.000 description 1
108090000969 Insulin-like growth factor-binding protein 4 Proteins 0.000 description 1
102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 1
108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 1
102220478985 Interleukin-4 receptor subunit alpha_L64A_mutation Human genes 0.000 description 1
229940122254 Intermediate acting insulin Drugs 0.000 description 1
102220475856 Keratin, type I cytoskeletal 10_R21A_mutation Human genes 0.000 description 1
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
235000019687 Lamb Nutrition 0.000 description 1
208000006302 Laron syndrome Diseases 0.000 description 1
208000035369 Leprechaunism Diseases 0.000 description 1
FQZPTCNSNPWHLJ-AVGNSLFASA-N Leu-Gln-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O FQZPTCNSNPWHLJ-AVGNSLFASA-N 0.000 description 1
CQGSYZCULZMEDE-UHFFFAOYSA-N Leu-Gln-Pro Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)N1CCCC1C(O)=O CQGSYZCULZMEDE-UHFFFAOYSA-N 0.000 description 1
CGHXMODRYJISSK-NHCYSSNCSA-N Leu-Val-Asp Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC(O)=O CGHXMODRYJISSK-NHCYSSNCSA-N 0.000 description 1
URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
206010024604 Lipoatrophy Diseases 0.000 description 1
101500023492 Lithobates catesbeianus Growth hormone-releasing peptide Proteins 0.000 description 1
101500021084 Locusta migratoria 5 kDa peptide Proteins 0.000 description 1
102000016261 Long-Acting Insulin Human genes 0.000 description 1
108010092217 Long-Acting Insulin Proteins 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
BOJYMMBYBNOOGG-DCAQKATOSA-N Lys-Pro-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O BOJYMMBYBNOOGG-DCAQKATOSA-N 0.000 description 1
HKXSZKJMDBHOTG-CIUDSAMLSA-N Lys-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CCCCN HKXSZKJMDBHOTG-CIUDSAMLSA-N 0.000 description 1
TVHCDSBMFQYPNA-RHYQMDGZSA-N Lys-Thr-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O TVHCDSBMFQYPNA-RHYQMDGZSA-N 0.000 description 1
JHNOXVASMSXSNB-WEDXCCLWSA-N Lys-Thr-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O JHNOXVASMSXSNB-WEDXCCLWSA-N 0.000 description 1
102220573949 MICOS complex subunit MIC10_S69A_mutation Human genes 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
YJNDFEWPGLNLNH-IHRRRGAJSA-N Met-Tyr-Cys Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CS)C(O)=O)CC1=CC=C(O)C=C1 YJNDFEWPGLNLNH-IHRRRGAJSA-N 0.000 description 1
208000021642 Muscular disease Diseases 0.000 description 1
201000009623 Myopathy Diseases 0.000 description 1
206010068871 Myotonic dystrophy Diseases 0.000 description 1
XZFYRXDAULDNFX-UHFFFAOYSA-N N-L-cysteinyl-L-phenylalanine Natural products SCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XZFYRXDAULDNFX-UHFFFAOYSA-N 0.000 description 1
BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
102220506263 N-alpha-acetyltransferase 50_P28A_mutation Human genes 0.000 description 1
102220506264 N-alpha-acetyltransferase 50_Y31A_mutation Human genes 0.000 description 1
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
206010029748 Noonan syndrome Diseases 0.000 description 1
102000007399 Nuclear hormone receptor Human genes 0.000 description 1
108020005497 Nuclear hormone receptor Proteins 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
102220567144 Ornithine decarboxylase antizyme 1_L57A_mutation Human genes 0.000 description 1
102220482871 Ornithine decarboxylase antizyme 1_M59A_mutation Human genes 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000004286 Osteochondrodysplasias Diseases 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
JEGFCFLCRSJCMA-IHRRRGAJSA-N Phe-Arg-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)O)N JEGFCFLCRSJCMA-IHRRRGAJSA-N 0.000 description 1
KAHUBGWSIQNZQQ-KKUMJFAQSA-N Phe-Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 KAHUBGWSIQNZQQ-KKUMJFAQSA-N 0.000 description 1
DXWNFNOPBYAFRM-IHRRRGAJSA-N Phe-Val-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N DXWNFNOPBYAFRM-IHRRRGAJSA-N 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
201000010769 Prader-Willi syndrome Diseases 0.000 description 1
DCHQYSOGURGJST-FJXKBIBVSA-N Pro-Thr-Gly Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O DCHQYSOGURGJST-FJXKBIBVSA-N 0.000 description 1
206010036790 Productive cough Diseases 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
102100034060 Putative glutathione hydrolase 3 proenzyme Human genes 0.000 description 1
206010037596 Pyelonephritis Diseases 0.000 description 1
102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
102220492229 Replication stress response regulator SDE2_R37A_mutation Human genes 0.000 description 1
102220644164 Rho guanine nucleotide exchange factor 10-like protein_T49W_mutation Human genes 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
102220468502 Serine/Arginine-related protein 53_E46A_mutation Human genes 0.000 description 1
241000607720 Serratia Species 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
206010072610 Skeletal dysplasia Diseases 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
101710142969 Somatoliberin Proteins 0.000 description 1
108010068542 Somatotropin Receptors Proteins 0.000 description 1
108090000787 Subtilisin Proteins 0.000 description 1
241000282887 Suidae Species 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
102220600976 Syndecan-4_N26A_mutation Human genes 0.000 description 1
108700005078 Synthetic Genes Proteins 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
ODXKUIGEPAGKKV-KATARQTJSA-N Thr-Leu-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)O)N)O ODXKUIGEPAGKKV-KATARQTJSA-N 0.000 description 1
NQQMWWVVGIXUOX-SVSWQMSJSA-N Thr-Ser-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O NQQMWWVVGIXUOX-SVSWQMSJSA-N 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
108010000499 Thromboplastin Proteins 0.000 description 1
102100030859 Tissue factor Human genes 0.000 description 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
AZGZDDNKFFUDEH-QWRGUYRKSA-N Tyr-Gly-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 AZGZDDNKFFUDEH-QWRGUYRKSA-N 0.000 description 1
102220549987 Usher syndrome type-1C protein-binding protein 1_Q15A_mutation Human genes 0.000 description 1
VLDMQVZZWDOKQF-AUTRQRHGSA-N Val-Glu-Gln Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N VLDMQVZZWDOKQF-AUTRQRHGSA-N 0.000 description 1
102220546633 Voltage-dependent L-type calcium channel subunit beta-2_L54A_mutation Human genes 0.000 description 1
102220580918 Voltage-dependent T-type calcium channel subunit alpha-1H_R56A_mutation Human genes 0.000 description 1
102220580965 Voltage-dependent T-type calcium channel subunit alpha-1H_S33A_mutation Human genes 0.000 description 1
102220580716 Voltage-dependent T-type calcium channel subunit alpha-1H_S51A_mutation Human genes 0.000 description 1
201000011032 Werner Syndrome Diseases 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
101001105586 Xenopus laevis 60S ribosomal protein L18-A Proteins 0.000 description 1
ISXSJGHXHUZXNF-LXZPIJOJSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate;hydrochloride Chemical compound Cl.C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 ISXSJGHXHUZXNF-LXZPIJOJSA-N 0.000 description 1
UXZMLECYBHANRH-UHFFFAOYSA-K [B+3].[O-]C(=O)C(F)(F)F.[O-]C(=O)C(F)(F)F.[O-]C(=O)C(F)(F)F Chemical compound [B+3].[O-]C(=O)C(F)(F)F.[O-]C(=O)C(F)(F)F.[O-]C(=O)C(F)(F)F UXZMLECYBHANRH-UHFFFAOYSA-K 0.000 description 1
GELXFVQAWNTGPQ-UHFFFAOYSA-N [N].C1=CNC=N1 Chemical compound [N].C1=CNC=N1 GELXFVQAWNTGPQ-UHFFFAOYSA-N 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
201000011040 acute kidney failure Diseases 0.000 description 1
208000012998 acute renal failure Diseases 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
238000009098 adjuvant therapy Methods 0.000 description 1
201000005255 adrenal gland hyperfunction Diseases 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
230000032683 aging Effects 0.000 description 1
108010024078 alanyl-glycyl-serine Proteins 0.000 description 1
108010083553 alanyl-histidyl-(2-naphthyl)alanyl-tryptophyl-phenylalanyl-lysinamide Proteins 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
238000005915 ammonolysis reaction Methods 0.000 description 1
210000004381 amniotic fluid Anatomy 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
239000003708 ampul Substances 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
230000001188 anti-phage Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
235000009697 arginine Nutrition 0.000 description 1
108010068380 arginylarginine Proteins 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
108010038633 aspartylglutamate Proteins 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
239000008228 bacteriostatic water for injection Substances 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
125000002619 bicyclic group Chemical group 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
239000012472 biological sample Substances 0.000 description 1
229920001222 biopolymer Polymers 0.000 description 1
239000002981 blocking agent Substances 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
238000006664 bond formation reaction Methods 0.000 description 1
230000008468 bone growth Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
238000010322 bone marrow transplantation Methods 0.000 description 1
230000010072 bone remodeling Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
239000008366 buffered solution Substances 0.000 description 1
DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
YSMHTFWPDRJCMN-UHFFFAOYSA-N butan-2-yl carbonochloridate Chemical compound CCC(C)OC(Cl)=O YSMHTFWPDRJCMN-UHFFFAOYSA-N 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
230000023852 carbohydrate metabolic process Effects 0.000 description 1
235000021256 carbohydrate metabolism Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
210000000845 cartilage Anatomy 0.000 description 1
238000012219 cassette mutagenesis Methods 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000030570 cellular localization Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
125000004803 chlorobenzyl group Chemical group 0.000 description 1
125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
239000003593 chromogenic compound Substances 0.000 description 1
238000001142 circular dichroism spectrum Methods 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
238000011284 combination treatment Methods 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
238000010668 complexation reaction Methods 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
238000011109 contamination Methods 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
150000003983 crown ethers Chemical class 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
238000012258 culturing Methods 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
230000001351 cycling effect Effects 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
239000007933 dermal patch Substances 0.000 description 1
238000013461 design Methods 0.000 description 1
230000000368 destabilizing effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
229960000452 diethylstilbestrol Drugs 0.000 description 1
BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000000539 dimer Substances 0.000 description 1
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 1
MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000012202 endocytosis Effects 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
239000005038 ethylene vinyl acetate Substances 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
210000001733 follicular fluid Anatomy 0.000 description 1
229920001002 functional polymer Polymers 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
229960000346 gliclazide Drugs 0.000 description 1
206010061989 glomerulosclerosis Diseases 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
230000004153 glucose metabolism Effects 0.000 description 1
108010057083 glutamyl-aspartyl-leucine Proteins 0.000 description 1
108010038088 glutamyl-glycyl-seryl-leucyl-glutamine Proteins 0.000 description 1
108010079547 glutamylmethionine Proteins 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 1
108010079413 glycyl-prolyl-glutamic acid Proteins 0.000 description 1
108010010147 glycylglutamine Proteins 0.000 description 1
108010015153 growth hormone releasing hexapeptide Proteins 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
230000005986 heart dysfunction Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
235000014304 histidine Nutrition 0.000 description 1
102000047065 human IGFBP1 Human genes 0.000 description 1
102000057148 human IGFBP3 Human genes 0.000 description 1
229910000042 hydrogen bromide Inorganic materials 0.000 description 1
229920001477 hydrophilic polymer Polymers 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000006058 immune tolerance Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
239000007943 implant Substances 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
208000000509 infertility Diseases 0.000 description 1
230000036512 infertility Effects 0.000 description 1
208000021267 infertility disease Diseases 0.000 description 1
239000003978 infusion fluid Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
108091008406 insulin binding proteins Proteins 0.000 description 1
230000003914 insulin secretion Effects 0.000 description 1
230000002608 insulinlike Effects 0.000 description 1
238000012482 interaction analysis Methods 0.000 description 1
201000006334 interstitial nephritis Diseases 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
230000031146 intracellular signal transduction Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
238000002955 isolation Methods 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
108010027338 isoleucylcysteine Proteins 0.000 description 1
229940006445 isophane insulin Drugs 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
238000012933 kinetic analysis Methods 0.000 description 1
150000003951 lactams Chemical class 0.000 description 1
108010073093 leucyl-glycyl-glycyl-glycine Proteins 0.000 description 1
108010090333 leucyl-lysyl-proline Proteins 0.000 description 1
238000000670 ligand binding assay Methods 0.000 description 1
208000022215 lipoatrophic diabetes Diseases 0.000 description 1
201000009099 lipoatrophic diabetes mellitus Diseases 0.000 description 1
244000144972 livestock Species 0.000 description 1
208000018773 low birth weight Diseases 0.000 description 1
231100000533 low birth weight Toxicity 0.000 description 1
230000005980 lung dysfunction Effects 0.000 description 1
210000004880 lymph fluid Anatomy 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000013507 mapping Methods 0.000 description 1
239000003550 marker Substances 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
230000006609 metabolic stress Effects 0.000 description 1
UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
230000009456 molecular mechanism Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
230000021332 multicellular organism growth Effects 0.000 description 1
230000004220 muscle function Effects 0.000 description 1
230000037257 muscle growth Effects 0.000 description 1
UPXAZUFKXWLNMF-UHFFFAOYSA-N n'-propan-2-ylmethanediimine Chemical compound CC(C)N=C=N UPXAZUFKXWLNMF-UHFFFAOYSA-N 0.000 description 1
210000004898 n-terminal fragment Anatomy 0.000 description 1
210000004897 n-terminal region Anatomy 0.000 description 1
230000014399 negative regulation of angiogenesis Effects 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
210000004498 neuroglial cell Anatomy 0.000 description 1
208000018360 neuromuscular disease Diseases 0.000 description 1
230000004112 neuroprotection Effects 0.000 description 1
FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
239000000346 nonvolatile oil Substances 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
108020004017 nuclear receptors Proteins 0.000 description 1
238000010534 nucleophilic substitution reaction Methods 0.000 description 1
210000004248 oligodendroglia Anatomy 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000003538 oral antidiabetic agent Substances 0.000 description 1
229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
210000000963 osteoblast Anatomy 0.000 description 1
229940092253 ovalbumin Drugs 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
230000016087 ovulation Effects 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
238000004810 partition chromatography Methods 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
102000023856 peptide binding proteins Human genes 0.000 description 1
108091008399 peptide binding proteins Proteins 0.000 description 1
230000009984 peri-natal effect Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
210000000578 peripheral nerve Anatomy 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
210000001322 periplasm Anatomy 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
235000020030 perry Nutrition 0.000 description 1
108700010839 phage proteins Proteins 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
108010011110 polyarginine Proteins 0.000 description 1
229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
229920005990 polystyrene resin Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
201000009395 primary hyperaldosteronism Diseases 0.000 description 1
208000037821 progressive disease Diseases 0.000 description 1
108010029020 prolylglycine Proteins 0.000 description 1
108010090894 prolylleucine Proteins 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
230000012846 protein folding Effects 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
230000000541 pulsatile effect Effects 0.000 description 1
230000006340 racemization Effects 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
239000000700 radioactive tracer Substances 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000010837 receptor-mediated endocytosis Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
239000006176 redox buffer Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
239000012465 retentate Substances 0.000 description 1
102200147641 rs104894534 Human genes 0.000 description 1
102220009232 rs111430410 Human genes 0.000 description 1
102220293323 rs1191543342 Human genes 0.000 description 1
102220238268 rs1343544501 Human genes 0.000 description 1
102220321437 rs202047149 Human genes 0.000 description 1
102200118306 rs33919924 Human genes 0.000 description 1
102200082892 rs33930165 Human genes 0.000 description 1
102200082910 rs34948328 Human genes 0.000 description 1
102220034170 rs75368761 Human genes 0.000 description 1
102220029473 rs78794935 Human genes 0.000 description 1
239000012146 running buffer Substances 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
108700004121 sarkosyl Proteins 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
210000000582 semen Anatomy 0.000 description 1
238000011894 semi-preparative HPLC Methods 0.000 description 1
230000001235 sensitizing effect Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000002864 sequence alignment Methods 0.000 description 1
108010007375 seryl-seryl-seryl-arginine Proteins 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
210000003802 sputum Anatomy 0.000 description 1
208000024794 sputum Diseases 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000011146 sterile filtration Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
150000005846 sugar alcohols Chemical class 0.000 description 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
230000002483 superagonistic effect Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
210000001179 synovial fluid Anatomy 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
230000008685 targeting Effects 0.000 description 1
210000001138 tear Anatomy 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
125000004149 thio group Chemical group *S* 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
229940034199 thyrotropin-releasing hormone Drugs 0.000 description 1
239000003104 tissue culture media Substances 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
238000004448 titration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
230000008733 trauma Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
238000010200 validation analysis Methods 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1

Landscapes

Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

CA2702760A 1999-01-06 2000-01-05 Variants mutants du facteur de croissance i semblable a l'insuline (igf) Expired - Lifetime CA2702760C (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US11501099P	1999-01-06	1999-01-06
US60/115,010		1999-01-06
CA2356257A CA2356257C (fr)	1999-01-06	2000-01-05	Variants mutants du facteur de croissance i semblable a l'insuline (igf)

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2356257A Division CA2356257C (fr)	1999-01-06	2000-01-05	Variants mutants du facteur de croissance i semblable a l'insuline (igf)

Publications (2)

Publication Number	Publication Date
CA2702760A1 CA2702760A1 (fr)	2000-07-13
CA2702760C true CA2702760C (fr)	2015-02-24

Family

ID=42790543

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2702760A Expired - Lifetime CA2702760C (fr)	1999-01-06	2000-01-05	Variants mutants du facteur de croissance i semblable a l'insuline (igf)

Country Status (1)

Country	Link
CA (1)	CA2702760C (fr)

2000
- 2000-01-05 CA CA2702760A patent/CA2702760C/fr not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2702760A1 (fr)	2000-07-13

Publication	Publication Date	Title
CA2356257C (fr)	2012-10-16	Variants mutants du facteur de croissance i semblable a l'insuline (igf)
AU762351B2 (en)	2003-06-26	Insulin-like growth factor (IGF) I mutant variants
EP0972020B1 (fr)	2002-09-25	Molecules agonistes du facteur de croissance de l'insulinoide
US6750321B1 (en)	2004-06-15	Insulin-like growth factor agonist molecules
CA2702760C (fr)	2015-02-24	Variants mutants du facteur de croissance i semblable a l'insuline (igf)
AU2003236454B2 (en)	2006-04-06	Insulin-like growth factor (IGF) I mutant variants
EP1506972A1 (fr)	2005-02-16	Variants mutants du facteur de croissance insulinomimétique (IGF) de type I

Legal Events

Date	Code	Title	Description
2010-05-06	EEER	Examination request
2020-03-10	MKEX	Expiry	Effective date: 20200106